A longitudinal serological follow-up from the combined AFFIRM and STRATIFY-1 studies showed, however, that only 87% of patients who were anti-JCV antibody negative at baseline remained consistently negative every 6 months over a period of 18 months (53) meaning that nearly 13% could become positive during follow-up.
I wonder which one is more accurate. Is biogen intentionally suppressing numbers, or does ehealthme.com simply take every report as golden without any kind of verification?
The JC virus is very common in the general population, infecting almost 90% of us in childhood. It stays under control and latent because our immune system keeps it in check. This means we have a JC negative status. The virus is able to cross the blood brain barrier where it attacks myelin and destroys brain tissue.
New research shows that the risk of JCV reactivation due to Tysabri use is ten times higher than previously estimated. That not 1%, but 10% of all patients on Tysabri were seen to go from JCV negative status to JCV positive status while taking Tysabri. The drug is apparently what turns people from JC virus negative to positive. This makes sense, if you understand that what Tysabri is doing is holding back immune cells, and rendering them unable to stop a virus from reactivating.
Users browsing this forum: No registered users